3-氯-4-硝基苯甲腈 | 34662-29-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-4-硝基苯甲腈
• 英文名称: 3-Chlor-4-nitro-benzonitril
• 英文别名: 2-chloro-4-cyanonitrobenzene；1-chloro-5-cyano-2-nitrobenzene；3-Chloro-4-nitrobenzonitrile
• CAS: 34662-29-8
• 化学式: C₇H₃ClN₂O₂
• 分子量: 182.566
• InChiKey: PAIMPYHIOHKXAT-UHFFFAOYSA-N

物化性质

• 沸点：
  319.7±27.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  3-氯-4-硝基苯甲腈 在 10% palladium on activated carbon 盐酸 、 lithium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 23.0~100.0 ℃ 、275.8 kPa 条件下， 反应 38.5h， 生成 甲基1-乙基-1H-苯并三唑-6-羧酸酯
  参考文献：
  名称：

  Novel benzotriazoles anti-inflammatory compounds

  摘要：

  公开号：

  EP1247810B1
• 作为产物：
  描述：

  3-氯-4-硝基苯胺 生成 3-氯-4-硝基苯甲腈
  参考文献：
  名称：

  Claus; Kurz, Journal fur praktische Chemie (Leipzig 1954), 1888, vol. <2> 37, p. 197

  摘要：

  DOI：

文献信息

• Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
  申请人：——

  公开号：US20030236260A1

  公开（公告）日：2003-12-25

  Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

  治疗IL-6相关疾病的方法涉及EP4受体配体，包括EP4受体拮抗剂。用于确定试验化合物对PGE2诱导的全血细胞活化效果的测定。
• Benzimidazole and pyridylimidazole derivatives
  申请人：——

  公开号：US20030069257A1

  公开（公告）日：2003-04-10

  This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I 1 The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA A receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA A receptors in tissue sections.

  这项发明涉及苯并咪唑、吡啶咪唑和相关的双环杂环芳烃化合物，所有这些化合物都可以用公式I描述。该发明特别涉及与GABA受体的苯二氮卓位点具有高选择性和高亲和力结合的化合物。该发明还涉及包含这些化合物的药物组合物，以及将这些化合物用于治疗某些中枢神经系统（CNS）疾病。公式I化合物的新制备方法也已披露。此外，该发明还涉及将苯并咪唑、吡啶咪唑和相关的双环杂环芳烃化合物与一个或多个其他CNS药剂结合以增强其他CNS药剂效果的用途。此外，该发明还涉及将这些化合物用作GABA受体在组织切片中的定位探针的用途。
• Synthesis and potent antifungal activity against<i>Candida</i>species of some novel 1<i>H</i>-benzimidazoles
  作者：Hakan Göker、Mehmet Alp、Zeynep Ateş-Alagöz、Sulhiye Yıldız

  DOI：10.1002/jhet.179

  日期：2009.9

  A series of 47 novel N1-alkylated-2-aryl-5(6)-substituted-1H-benzimidazoles and their three novel indole analogues were synthesized and evaluated for in vitro antifungal activities against Candida species by the tube dilution method. The results showed that compounds 79 and 80, having pyridine at the position C-2, of benzimidazoles exhibited the greatest activity with MIC values of 6.25–3.12 μg/mL

  合成了一系列47种新颖的N 1-烷基化-2-芳基-5（6）-取代的1 H-苯并咪唑及其三种新颖的吲哚类似物，并通过试管稀释法评估了其对念珠菌的体外抗真菌活性。结果表明，苯并咪唑类化合物在C-2位置具有吡啶的化合物79和80表现出最大的活性，MIC值为6.25–3.12μg/ mL。吲哚类似物108-110没有抑制活性。J.杂环化​​学，（2009）。
• Bicyclic compounds as NR2B receptor antagonists
  申请人：——

  公开号：US20040204409A1

  公开（公告）日：2004-10-14

  This invention provides a compound of the formula (I): 1 wherein R 1 and R 2 independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like: These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物，其化学式为(I):其中R1和R2分别表示氢原子或类似物；X表示共价键或类似物；A表示具有8至12个环原子的双环、芳香、饱和或部分不饱和的杂环或碳环基团；或类似物；B表示具有5至6个环原子的苯基或杂环基团；或类似物。这些化合物对于治疗由NMDA NR2B受体过度活化引起的疾病情况，如疼痛等在哺乳动物中具有用途。这项发明还提供了包含上述化合物的药物组合物。
• Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
  申请人：Feenstra W. Roelof

  公开号：US20060122189A1

  公开（公告）日：2006-06-08

  The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine-D 2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1): wherein the symbols have the meanings given in the specification. and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.

  这项发明涉及一组具有双重作用的新型苯基哌嗪衍生物：对5- 羟色胺再摄取抑制和对多巴胺-D2受体的部分激动作用。该发明还涉及使用本文所披露的化合物制备药物以产生益处。这些化合物具有一般式（1）：其中符号的含义如规范中所述。以及该式化合物及其互变异构体、立体异构体和N-氧化物的药理学可接受的盐、水合物和溶剂化合物。